Skip to content

Regeneron & Bayer announce clinical results in CRVO & DME with VEGF Trap-Eye

Results of a Phase 3 study in CRVO and a Phase 2 study in DME have provided a positive outcome for Regeneron’s VEGF Trap-Eye experimental compound, in addition to earning the company $20M in milestone payments from Bayer Healthcare. The CRVO trial showed that 56.1% of patients treated with VEGF Trap-Eye gained at least 15 letters of vision compared to the control group at 12.3% while the Phase 2 DME study showed that patients in all the VEGF Trap-Eye dose regimens either maintained or increased vision gains by the end of 1 year.